Sanofi in talks to buy Indian OTC business

Sanofi ($SNY) is in the throes of another emerging markets deal. The French drugmaker's Indian unit Aventis Pharma is talking to buy the over-the-counter business of Universal Medicare. At about 5 billion rupees ($109 million), the buyout wouldn't be large. But it would give Sanofi's OTC operations in India a needed boost.

Sanofi would get about 30 of Universal Medicare's brands, with sales of about 1 billion to 1.15 billion rupees, or up to $25 million, Reuters sources said. "Sanofi's OTC business in India was quite nominal," one told the news service. "And the products are profit-making."

The deal is expected to be wrapped in a couple of days. It would be something of a double dip for Sanofi, which has been both branching out into emerging markets and strengthening its consumer healthcare business to help offset sales lost to new-and-impending generic rivals to some key drugs. India's over-the-counter market is growing at a 17% to 18% annual clip.

As Reuters notes, Sanofi is far from alone in targeting OTC markets in the developing world. Late last year, Reckitt Benckiser bought Paras Pharmaceuticals for $726 million, while Johnson & Johnson ($JNJ) in May agreed to buy some Russian-market over-the-counter brands from India-based JB Chemicals and Pharmaceuticals.

- read the Reuters news
- get more from the Economic Times

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

The FDA approved Lundbeck's Vyepti, formerly known as eptinezumab, as the first IV therapy to prevent migraines in adults.